PRAME nuclear receptor transcriptional regulator (PRAME)

PRAME nuclear receptor transcriptional regulator (commonly abbreviated as PRAME) is a tumor-associated antigen encoded on human chromosome 22 that is predominantly expressed in various cancers and normal testis tissue but is absent or minimally expressed in other normal tissues[3][7]. It belongs to the cancer/testis antigen family and functions as a transcription regulator via interaction with retinoic acid receptor alpha, inhibiting retinoic acid signaling, thereby promoting tumorigenesis and maintaining pluripotency in embryonic and germ cells[2][6]. PRAME is characterized by multiple leucine-rich repeats, localizes to both nucleus and cytoplasm, and participates in immune evasion mechanisms, making it an attractive target for cancer immunotherapy[3][6]. Expression of PRAME is a negative prognostic factor in several malignancies and serves as a biomarker for patient stratification in cancer therapy[4][6]. Recombinant PRAME protein, often used in conjunction with adjuvants, is in clinical development as a cancer vaccine antigen[5].

Other names

Preferentially expressed antigen in melanomaMelanoma antigen preferentially expressed in tumorsCancer/testis antigen PRAME

Targets for immunotherapy (induces T-cell-mediated cytotoxicity against tumor cells expressing PRAME)[4][5]; Modulation of retinoic acid receptor signaling (suppression of retinoic acid receptor alpha, RARA, function)[2]